These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 22145501

  • 21. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
    Cozzolino M, Messa P, Brancaccio D, Cannella G, Bolasco P, Di Luca M, Costanzo AM, Paparatti Ud, Festa V, Gualberti G, Mazzaferro S, FARO Study Group.
    Blood Purif; 2014; 38(1):37-45. PubMed ID: 25277167
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Achievements of kidney disease outcomes quality initiative goals in hemodialysis patients at Jordan University Hospital.
    Wahbeh AM, Ibrahim AT, Salah NG.
    Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1275-9. PubMed ID: 22089803
    [Abstract] [Full Text] [Related]

  • 24. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N, Wagner M, Griffith JL, Miskulin DC, Hodsman A, Ansell D, Naimark DM.
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [Abstract] [Full Text] [Related]

  • 25. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL, Hristova M, Ho LT, Sprague SM.
    Am J Nephrol; 2007 Mar; 27(1):36-43. PubMed ID: 17215573
    [Abstract] [Full Text] [Related]

  • 26. Assessment of bone mineral metabolism derangements by K/DOQI guidelines in haemodialysis patients at Rawalpindi.
    Khan DA, Fatima-Tuz-Zuhra, Khan FA, Saif I.
    J Pak Med Assoc; 2009 Feb; 59(2):64-7. PubMed ID: 19260564
    [Abstract] [Full Text] [Related]

  • 27. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
    Al Aly Z, González EA, Martin KJ, Gellens ME.
    Am J Nephrol; 2004 Feb; 24(4):422-6. PubMed ID: 15308874
    [Abstract] [Full Text] [Related]

  • 28. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T.
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [Abstract] [Full Text] [Related]

  • 29. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?
    Fouque D, Roth H, Pelletier S, London GM, Hannedouche T, Jean G, Bouchet JL, Drüeke T.
    Nephrol Dial Transplant; 2013 Feb; 28(2):360-7. PubMed ID: 23136211
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness of a chronic kidney disease clinic in achieving K/DOQI guideline targets at initiation of dialysis--a single-centre experience.
    Lee W, Campoy S, Smits G, Vu Tran Z, Chonchol M.
    Nephrol Dial Transplant; 2007 Mar; 22(3):833-8. PubMed ID: 17127695
    [Abstract] [Full Text] [Related]

  • 31. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
    Deger SM, Mutluay R, Derici U, Mandiralioglu F, Arinsoy T, Sindel S.
    Med Princ Pract; 2011 Mar; 20(1):85-9. PubMed ID: 21160221
    [Abstract] [Full Text] [Related]

  • 32. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD, Alvarez-Ude F, Torregrosa V, Gil MT, Carretón MA, Moledous A, Nuñez C, Devesa R, Albiach B.
    J Nephrol; 2007 Mar; 20(4):453-61. PubMed ID: 17879212
    [Abstract] [Full Text] [Related]

  • 33. Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making?
    Morton AR, Murphy S, Hirsch D, Leblanc M, Barré P, Lok C, Hercz G, Hodsman A, Reslerova M, Levin A.
    Hemodial Int; 2010 Apr; 14(2):200-10. PubMed ID: 20337745
    [Abstract] [Full Text] [Related]

  • 34. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.
    Semin Dial; 2005 Apr; 18(3):226-38. PubMed ID: 15934970
    [Abstract] [Full Text] [Related]

  • 35. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T, Yamamoto H.
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [Abstract] [Full Text] [Related]

  • 36. The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes.
    Van Biesen W, Vanholder R, Veys N, Verbeke F, Delanghe J, De Bacquer D, Lameire N.
    Nephrol Dial Transplant; 2006 Jan; 21(1):77-83. PubMed ID: 16221704
    [Abstract] [Full Text] [Related]

  • 37. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S, Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R.
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [Abstract] [Full Text] [Related]

  • 38. National haemodialysis guidelines: an assessment of compliance from 2001-2003.
    Bannister KM, Snelling P, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2006 Apr; 11(2):90-6. PubMed ID: 16669967
    [Abstract] [Full Text] [Related]

  • 39. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.
    Yamada S, Ueki K, Tokumoto M, Suehiro T, Kimura H, Taniguchi M, Fujimi S, Kitazono T, Tsuruya K.
    Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334
    [Abstract] [Full Text] [Related]

  • 40. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, LoDeserto C, Pozzato M, Rombolà G, Costanzo AM, di Luzio Paparatti U, Mazzaferro S, FARO Study Group.
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.